Abstract: Provided herein is a compound for the use in the treatment of non-alcoholic fatty liver disease (NAFLD) and related diseases such NAFL and NASH. Pharmaceutical compositions, single unit dosage forms, and kit suitable for use for the treatment of NAFLD and related diseases are also disclosed.

Abstract: The present invention relates to a method of identifying a predisposition for developing type 2 diabetes mellitus in a subject, said method comprising the step of assessing in a sample obtained from said subject the amount of one or more metabolite(s) selected from (a) a first group comprising the metabolites glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2, phosphatidylcholine acyl-alkyl C36:3 and isobaric metabolites having the same molecular mass as glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2 or phosphatidylcholine acyl-alkyl C36:3 but different chemical formula; and/or (b) a second group comprising the metabolite acetylcarnitine C2 and an isobaric m

Abstract: The present invention relates to a method of identifying a predisposition for developing type 2 diabetes mellitus in a subject, said method comprising the step of assessing in a sample obtained from said subject the amount of one or more metabolite(s) selected from (a) a first group comprising the metabolites glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2, phosphatidylcholine acyl-alkyl C36:3 and isobaric metabolites having the same molecular mass as glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2 or phosphatidylcholine acyl-alkyl C36:3 but different chemical formula; and/or (b) a second group comprising the metabolite acetylcarnitine C2 and an isobaric m

Abstract: The present invention provides a system for disinfecting shopping carts. In one embodiment, the system comprises a treatment station for applying a disinfectant to a shopping cart and a conveyor system for transporting carts relative to the treatment station at two different speeds so as to effect a nesting operation. In another embodiment, the system comprises a treatment station that is comprised of a first modular unit and a second modular unit that each perform different functions but can readily joined to one another to form a treatment station with the desired features for a particular application. In yet another embodiment, certain features of the modular units are symmetrical relative to a lateral plane to facilitate the joining of the units to one another in different orders. A further embodiment comprises a treatment station with a molded structure.

Abstract: An analog to digital converter having a group of subrange analysis blocks and reference voltage and offset voltage selection blocks. Each subrange analyses block produces an output representative of a range of bits in a digital output of the analog digital converter. The reference voltage and offset voltage selection blocks enable the operating conditions for the next subrange analysis block to be optimized for both linearity and operating speed.